KPKaran Pandher

Karan Pandher

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Karan Pandher has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Prayer nodules: a case report highlighting the importance of thorough history-taking

    by Rachel K Holbrook, Karan Pandher, Natalie H Matthews

    Prayer (or athlete’s) nodules are hyperplastic, flesh-colored dermal masses that arise after repetitive trauma to an area, commonly occurring with prayer rituals or sports-related activities such as boxing. These nodules can appear worrisome and may prompt testing for malignancy if a detailed history is not gathered. We present a case of a prayer’s nodule to demonstrate the importance of thorough social history-taking and adjusting treatment plans to align with the patient's best interest while also addressing their concerns.

  • Review of the holistic management of pediatric atopic dermatitis

    by Armaan Guraya, Karan Pandher, Caroline L. Porter, Sarah Taylor, Joseph Jorizzo, Lindsay Strowd, Rajesh Balkrishnan, Steven Feldman

    Atopic Dermatitis (AD) is a chronic inflammatory skin disease that is broadly characterized by eczematous lesions and pruritus. This condition is detrimental in a multitude of ways, including patient quality of life (QOL), family QOL, economic burden, and psychosocial afflictions. Current management needs to incorporate a holistic approach which considers the financial, emotional, and physical limitations of both the treatments and the provider. A non-systematic search was conducted on the holistic management of pediatric AD. Various search queries were used such as the key terms of “atopic dermatitis,” “pediatric,” “eczema,” “management,” and more to encompass treatments, adherence, and comorbidities. There is an association with AD and depression in children, and its prevalence should be screened for routinely in children with AD. Collaboration with other specialties may prove to be prudent in addressing this comorbidity. Objective quality of life scores can open the door to much needed conversation with patients to get them the help they need. In expanding our scope, we find the extended consequences of AD have a ripple effect on families of pediatric patients. Lastly, we introduce a model for improving treatment adherence. Conclusion: Patient quality-of-life can be negatively affected by the symptoms, expense, stigma, and time commitment, and inconvenience imposed by complicated treatment regimens. To ensure proper, holistic management of pediatric AD, multiple factors must be considered; seasonal changes, lifestyle modifications, and the psychosocial impact are just a couple of factors that require monitoring. What is Known: • Atopic dermatitis impacts patients and their families in quality of life, economically, and psychosocially. • Current treatment revolves largely around treating physical manifestation of disease with first line measures such as topical steroids. What is New: • The holistic management of AD incorporates a good physician-patient relationship, frequent follow-up, and providing structured written plans. • We introduce the house building model for improving treatment adherence. Key points Pediatric AD can be managed in a more holistic manner which incorporates several factors from the lives of patients and their families. Pediatric patients suffer from many physical and mental comorbidities which should be screened for. Adherence with treatment may be improved by following a model which emphasizes establishing a good physician-patient relationship, frequent follow-up, and providing structured written plans.


  • Open Access

    Desenvolvimento de pênfigo vegetante após cirurgia micrográfica de Mohs e crioterapia

    by Nathan Jetter, Felipe Bochnia Cerci, Karan Pandher, Aleksandar L. Krunic

  • Open Access

    Pemphigus vegetans developing after Mohs micrographic surgery and cryotherapy

    by Nathan Jetter, Felipe Bochnia Cerci, Karan Pandher, Aleksandar L. Krunic


  • Open Access

    Temporal Trends of Revision Etiologies in Total Knee Arthroplasty at a Single High-Volume Institution: An Epidemiological Analysis

    by Benjamin Kerzner, Kyle N. Kunze, Michael B. O’sUllivan, Karan Pandher, Brett R. Levine


  • Controversial cardiovascular and hematologic comorbidities in atopic dermatitis

    by Karan Pandher, Rima I. Ghamrawi, Courtney E. Heron, Steven R. Feldman

    Atopic dermatitis’ (AD) systemic involvement is wide-reaching. The cardiovascular and hematological comorbidities of AD have potential for considerable economic and physical burden; however, data surrounding the association between these comorbidities and AD is controversial. This review discusses the cardiovascular and hematological comorbidities of AD, detailing the conflicting evidence, pathophysiology, and connection to medications. A PubMed search was conducted for studies detailing the association of cardiovascular and hematological comorbidities with AD, providing approximately 30 results. Additional searches were conducted for studies discussing the pathophysiology of these comorbidities and possible connections to AD medications. Various studies highlight either positive, negative, or no association of AD with hypertension, stroke, myocardial infarction, heart failure, and thrombosis. Coronary heart disease, angina, peripheral artery disease, and anemia are consistently positively associated with AD. However, the attributable risks of AD for stroke, myocardial infarction, heart failure, and atrial fibrillation are low (25 per 100,000 persons [99% CI 6–44], 12 per 100,000 persons [99% CI − 4–27], 40 per 100,000 persons [99% CI 22–57], and 37 per 100,000 persons [99% CI 15–55]), respectively. The pathophysiology underlying these potential associations is not entirely clear. Corticosteroids, cyclosporine, and antimetabolites, all used to treat AD, may also be associated with many of these comorbidities. AD’s controversial associations with cardiovascular and hematological diseases complicates management as it is difficult to define recommendations for screening of these comorbidities. A better understanding may help lessen the economic and physical burden of these comorbidities in AD patients.


  • Open Access

    Understanding views of patients on biologics for psoriasis amid the COVID‐19 pandemic

    by K. Pandher, C.L. Porter, H.S. Patel, W.W. Huang, S.R. Feldman